A Pharmacokinetic Rationale for Proactive Therapeutic Drug Monitoring of Anti-TNF Drugs Response

被引：0
|
作者：
Papamichael, Konstantinos [1 ]
Cheifetz, Adam S. [1 ]
机构：
[1] Harvard Med Sch, Div Gastroenterol, Dept Med, Ctr Inflammatory Bowel Dis, Boston, MA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2017年 / 112卷 / 12期
关键词：
INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; INFLIXIMAB; IBD;
D O I：
10.1038/ajg.2017.375
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1893 / 1894
页数：2
相关论文
共 50 条
  • [41] Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA)
    Nassar-Sheikh Rashid, A.
    Schonenberg-Meinema, D.
    Bergkamp, S. C.
    Bakhlakh, S.
    de Vries, A.
    Rispens, T.
    Kuijpers, T. W.
    Wolbink, G.
    van den Berg, J. M.
    PEDIATRIC RHEUMATOLOGY, 2021, 19 (01)
  • [42] Usual suspects: anti-TNF drugs
    Onat, Ahmet Mesut
    CLINICAL RHEUMATOLOGY, 2010, 29 (04) : 447 - 448
  • [43] Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study
    Fuentes-Valenzuela, Esteban
    Javier Garcia-Alonso, Francisco
    Maroto-Martin, Carlos
    Juan Casamayor, Laura
    Antonio Garrote, Jose
    Almendros Munoz, Rosendo
    De Prado, Angel
    Vara Castrodeza, Alejando
    Angeles Marinero, Maria
    Calleja Carbajosa, Raquel
    Barrio, Jesus
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (10) : 1586 - 1593
  • [44] q Secondary loss of response to anti-TNF in inflammatory bowel diseases. Therapeutic drug monitoring. Utility in clinical practice
    Jimenez, M.
    Sierra-Ausin, M.
    Cano, N.
    Suarez, P.
    Fernandez-Gundin, M.
    Saez-Villafane, M.
    Monteserin, L.
    Molina, G.
    Reyes, N.
    Viso, D.
    Jorquera, F.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S298 - S298
  • [45] Editorial: is there a role for monitoring intermediate anti-TNF drug concentrations in IBD?
    Rakowsky, Shana
    Cheifetz, Adam S.
    Papamichael, Konstantinos
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (08) : 1049 - 1050
  • [46] Monitoring of anti-TNF biological treatments
    A Ruiz del Agua
    D Pascual-Salcedo
    A Balsa
    I Ramos
    L Novalbos
    S Ramiro
    A Martínez
    L Simón
    D Nagore
    Journal of Translational Medicine, 8 (Suppl 1)
  • [47] Anti-TNF Antibodies and Autophagy: A Hidden Nexus for a Successful Therapeutic Response?
    Genua, Marco
    Becker, Christoph
    Vetrano, Stefania
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (03): : 237 - 238
  • [48] THERAPEUTIC DRUG-MONITORING OF ANTIARRHYTHMIC DRUGS RATIONALE AND CURRENT STATUS
    LATINI, R
    MAGGIONI, AP
    CAVALLI, A
    CLINICAL PHARMACOKINETICS, 1990, 18 (02) : 91 - 103
  • [49] Utility of therapeutic anti-TNF drug monitoring in hospitals with different degree of experience in the treatment of inflammatory bowel disease
    Vila, M.
    Bahi, A.
    Miquel, J. O.
    Busquets, D.
    Salo, J.
    Aldeguer, X.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S90 - S90
  • [50] Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
    Marquez-Megias, Silvia
    Nalda-Molina, Ricardo
    Sanz-Valero, Javier
    Mas-Serrano, Patricio
    Diaz-Gonzalez, Marcos
    Candela-Boix, Maria Remedios
    Ramon-Lopez, Amelia
    PHARMACEUTICS, 2022, 14 (05)
12345